New analyses from Phase III HAVEN studies support Hemlibra's sustained efficacy, safety and quality of life benefit in people with hemophilia A, with and without ...
Tuesday, 9 July 2019
Genentech Presents a Broad Range of Data for Hemlibra (Emicizumab-kxwh) Demonstrating Continued Benefits for People With Hemophilia A at the ISTH 2019 Congress - BioSpace
Genentech Presents a Broad Range of Data for Hemlibra (Emicizumab-kxwh) Demonstrating Continued Benefits for People With Hemophilia A at the ISTH 2019 Congress BioSpace
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment